Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients with Advanced Cancer
The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer.
The name of the study intervention used in this research study is:
Psilocybin (a tryptamine derivative)
100 Clinical Results associated with Cy Biopharma AG
0 Patents (Medical) associated with Cy Biopharma AG
100 Deals associated with Cy Biopharma AG
100 Translational Medicine associated with Cy Biopharma AG